Skip to main content
OpenTrials
Completed

NCT Number: NCT00022763

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

This study will evaluate T-20 in children.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Children's Hosp Los Angeles, Los Angeles, California, United States

Loading trial locations.

About this study

Children are stratified by age group (3 through 11 years and 12 through 16 years). Samples for HIV-1 genotype and phenotype resistance testing are obtained at screening to aid in the selection of concomitant antiretrovirals. Simultaneous to initiating T-20, all patients begin a "new" optimized antiretroviral regimen based on the patients' prior treatment history, historical resistance testing results, and the results of the testing performed at screening. Patients are followed for safety and other assessments at Weeks 1, 2, and 4, then monthly through Week 24 and bimonthly through Week 48. Pharmacokinetic sampling at selected study visits are performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are 3 through 16 years of age and have the consent of parent or guardian.
  • Have a viral load of at least 5000 copies/ml.
  • Have taken at least 2 of the 3 licensed anti-HIV drug classes for at least 3 months.
  • Have been on stable therapy for at least 4 weeks.

Treatment and study plan

Enfuvirtide

Drug

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343)

    Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)

    The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) for Enfuvirtide and Its Metabolite (Ro 50-6343)

    Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)

    The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was calculated from plasma concentration-time data (on Day 7) using standard non-compartmental pharmacokinetic methods.

  2. Time to Maximum Plasma Concentration (Tmax) for Enfuvirtide

    Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)

    Tmax is defined as actual sampling time to reach maximum observed analyte concentration.

  3. Minimum Plasma Concentration (Ctrough) for Enfuvirtide and Its Metabolite (Ro 50-6343)

    Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)

    Ctrough is defined as the lowest concentration that a drug reaches before the next dose is administered.

  4. AUC12h Ratio of Enfuvirtide Metabolite (Ro 50-6343)/ENF (Ro 29-9800)

    Time frame: Pre-dose (time 0), and 2, 4, 8, and 12 hours post-dose (Week 1)

    The ratio of the area under plasma concentration-time curve from time 0 to 12 hours of Enfuvirtide Metabolite (Ro 50-6343) versus enfuvirtide was calculated.

  5. Number of Participants With Adverse Events (AEs) and Serious AEs

    Time frame: Up to Week 4 after discontinuation of therapy

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.

  6. Number of Participants With Treatment Emergent Grade 3 or Grade 4 Laboratory Abnormalities

    Time frame: Up to Week 96

    Pediatric AIDS Clinical Trials Group (PACTG) toxicity grading scale was used for reviewing and grading clinically significant laboratory abnormalities. PACTG Grade 3 and Grade 4 were considered Severe and life threatening, respectively.

  7. Number of Participants Who Died

    Time frame: Up to Week 96

  8. Number of Participants Who Prematurely Withdrew Due to AE

    Time frame: Up to Week 96

  9. Number of Participants With Worst Local Injection Site Reactions

    Time frame: Up to Week 96

    Numbers of Participants With worst local injection site reactions were reported. Localized injection site reactions like erythema, induration, pruritus, nodule and cyst, and ecchymosis were recorded.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Collaborators

  • Trimeris

Registry information

Official study title

A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents

Important dates

Study start
2001
Primary completion
2004
First posted
Aug 31, 2001
Registry last updated
Feb 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.